pegylated liposomal doxorubicin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 42 Diseases   111 Trials   111 Trials   1691 News 


«12...56789101112131415...3132»
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Tumor penetrating utorubicin-loaded polymersomes for anti-cancer therapy (Poster Area) -  Jun 28, 2022 - Abstract #EACR2022EACR_687;    
    The brightest example, liposomal doxorubicin (Caelyx ®), is clinically approved for the treatment of several types of cancer...Conclusion We developed a tumor-specific nanoplatform that selectively delivers a novel drug candidate UTO to breast and peritoneal tumors and has an anti-cancer effect in a model of peritoneal carcinomatosis. Our study encourages further preclinical and clinical studies on UTO as a nanocarrier payload for precision cancer therapy with reduced drug side effects.
  • ||||||||||  Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
    Journal:  Fabrication of Doxorubicin-Loaded Lipid-Based Nanocarriers by Microfluidic Rapid Mixing. (Pubmed Central) -  Jun 25, 2022   
    The optimized LNC-Dox showed preferred release in acidic environments and better therapeutic efficacy compared to PEGylated liposomal Dox in vivo. Thus, this study provides a feasible approach to efficiently encapsulate doxorubicin into lipid-based nanocarriers fabricated by microfluidic rapid mixing.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker:  Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes. (Pubmed Central) -  Jun 23, 2022   
    Liposome-PD-1 siRNA monotherapy and PD-1 siRNA-Doxil (liposomal doxorubicin) combination therapy improved the survival significantly, compared to the control treatment (P < 0.001). Overall, these findings suggest that immunotherapy with siPD-1-loaded liposomes by enhancing T-cell-mediated antitumor immune responses could be considered as a promising strategy for the treatment of melanoma cancer.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Retrospective data, Review:  Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma. (Pubmed Central) -  Jun 22, 2022   
    Interstitial pneumonitis (IP), a potentially fatal complication of non-Hodgkin Lymphoma (NHL) patients received CHOP (cyclophosphamide and doxorubicin and vincristine and prednisone)-like chemotherapy, negatively affected patients' clinical outcome and quality of life...Among the 3 available patient-related risk factors, 6 disease-related risk factors and 3 drug-related risk factors, it was found that only drug-related risk factors were significantly associated with IP development: pegylated liposomes doxorubicin (PLD) replacement (RR = 3.25, 95% CI = 1.69-6.27, I 64%), rituximab (RTX) addition (RR = 4.24, 95% CI = 2.58-6.96, I 0) and granulocyte colony stimulating factor (G-CSF) administration (RR = 5.80, 95% CI = 3.05-11.05, I 0)...Clinicians should focus on these patients to detect and treat the IP development timely, which might bring benefit in patients' survival. PROSPERO, identifier CRD42022309884.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment closed, Trial completion date, Trial primary completion date, IO biomarker, Metastases:  ICON: Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer (clinicaltrials.gov) -  Jun 15, 2022   
    P2b,  N=82, Active, not recruiting, 
    Trial completion date: Dec 2027 --> Dec 2028 Completed --> Active, not recruiting | Trial completion date: Jan 2022 --> May 2027 | Trial primary completion date: Jan 2022 --> May 2022
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy (clinicaltrials.gov) -  Jun 3, 2022   
    P2,  N=24, Active, not recruiting, 
    The clinical utility of the AMC as a predictor of PLD-induced HFS appears limited, at least when given with ifosfamide. Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Jul 2022 --> Dec 2022
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Trial completion date, Trial primary completion date, Combination therapy, Tumor mutational burden, IO biomarker, Metastases:  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) (clinicaltrials.gov) -  Jun 3, 2022   
    P2,  N=115, Recruiting, 
    Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Jul 2022 --> Dec 2022 Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Biomarker, Journal, Tumor microenvironment:  Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy. (Pubmed Central) -  May 26, 2022   
    Furthermore, employing murine breast and fibrosarcoma tumor models as well as ultrasound shear wave elastography and contrast-enhanced ultrasound, we provide evidence that the approved nanomedicine Doxil can induce normalization in a dose-dependent manner by improving tumor perfusion as a result of tissue softening. Finally, we show that pretreatment with a normalizing dose of Doxil can improve the efficacy of immune checkpoint inhibition.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Trial completion date:  Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) -  May 25, 2022   
    P1/2,  N=28, Active, not recruiting, 
    Finally, we show that pretreatment with a normalizing dose of Doxil can improve the efficacy of immune checkpoint inhibition. Trial completion date: Apr 2022 --> Apr 2023
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg., cyclophosphamide / Generic mfg.
    Journal:  Translational development of a tumor junction opening technology. (Pubmed Central) -  May 21, 2022   
    Pretreatment with steroids and cyclophosphamide reduced anti-c-JO4 antibody response and blunted cytokine release. Our data indicate acceptable safety of our new treatment approach if immune reactions are monitored and counteracted with appropriate immune suppression.
  • ||||||||||  Promitil (pegylated liposomal mitomycin-c prodrug) / LipoMedix
    Journal:  Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy. (Pubmed Central) -  May 19, 2022   
    Dox and MLP are available in single drug liposomal formulations: pegylated liposomal Dox (PLD, Doxil®), clinically approved, and pegylated liposomal MLP (PL-MLP, Promitil®), in phase 1-2 clinical testing...The Ald-free formulation, PLD-MLP, displayed similar pharmacokinetic properties to PLAD-MLP, but its therapeutic activity was lower. PLAD-MLP is a novel multi-drug liposome formulation with attractive pharmacological properties and powerful antitumor activity and is a promising therapeutic tool for combination cancer chemotherapy.
  • ||||||||||  Ovastat (treosulfan) / Medac, Medexus
    Biomarker, Journal, Heterogeneity:  Interpatient Heterogeneity in Drug Response and Protein Biomarker Expression of Recurrent Ovarian Cancer. (Pubmed Central) -  May 15, 2022   
    The second-line combination therapy of carboplatin with gemcitabine was significantly superior to the combination of carboplatin with PEGylated liposomal doxorubicin (p < 0.0001) or paclitaxel (p = 0.0007)...Treosulfan showed the highest efficacy of all nonplatinum agents, with significant advantage over vinorelbine (p < 0.0001) and topotecan (p < 0.0001), the next best agents...Biological heterogeneity observed in recurrent ovarian cancers might explain the strong differences in the clinical drug response of these patients. Preclinical drug testing and biomarker profiling in the ovarian-cancer spheroid model might help in optimizing treatment management for individual patients.
  • ||||||||||  CDX-1140 / Celldex, Mobista (CDX-301) / Celldex
    Enrollment open, Combination therapy, Metastases:  CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer (clinicaltrials.gov) -  May 3, 2022   
    P1,  N=45, Recruiting, 
    Trial completion date: Apr 2022 --> Dec 2023 | Trial primary completion date: Apr 2022 --> Dec 2023 Not yet recruiting --> Recruiting
  • ||||||||||  nemvaleukin alfa (ALKS 4230) / Alkermes, Keytruda (pembrolizumab) / Merck (MSD)
    ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Available On Demand; 481a) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_5437;    
    P3
    Pts must have received ≥1 prior line of systemic therapy in the platinum-sensitive setting, ≤5 prior lines in the platinum-resistant setting, and prior bevacizumab, with radiographic progression on most recent therapy...Approximately 376 pts will be randomized (3:1:1:3) to receive nemvaleukin 6 μg/kg IV on days 1-5 and pembrolizumab 200 mg IV on day 1 of each 21-day cycle, pembrolizumab monotherapy, nemvaleukin monotherapy, or chemotherapy (pegylated liposomal doxorubicin, paclitaxel, topotecan, or gemcitabine) and stratified according to PD-L1 status, histologic subtype (high-grade vs non–high-grade serous), and chemotherapy (paclitaxel vs other)...The primary endpoint is investigator-assessed PFS (RECIST v1.1) in the nemvaleukin/pembrolizumab vs chemotherapy group. Secondary/exploratory endpoints include overall survival, other antitumor measures, safety, health-related quality of life, and pharmacokinetic/pharmacodynamic effects.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Clinical, Journal:  Using peptides to promote delivery and improve anti-tumour efficacy of liposomal drug. (Pubmed Central) -  Apr 23, 2022   
    Importantly, iv administration of piRGD-engrafted Caelyx was found to significantly inhibit tumour growth and prolong survival in both B16 and CT26 murine tumour models. Our results show that engraftment of piRGD onto Caelyx is a convenient strategy to enhance treatment efficacy.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  Metronomic PLD in Patients With Primary Endocrine Resistant ABC (clinicaltrials.gov) -  Apr 20, 2022   
    P2,  N=46, Recruiting, 
    Our results show that engraftment of piRGD onto Caelyx is a convenient strategy to enhance treatment efficacy. Trial completion date: Dec 2019 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Dec 2022
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Review, Journal, BRCA Biomarker, IO biomarker:  Predicting Response to Anthracyclines in Ovarian Cancer. (Pubmed Central) -  Apr 19, 2022   
    Immunochemistry, in particular HER-2 expression, could be of some help in predicting the response to such drugs, and high levels of mutated p53 appear after exposure to anthracyclines and impair their antitumor effect. Finally, organoids from OC are promising for drug testing and prediction of response to chemotherapy.
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg.
    Review, Journal:  Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology. (Pubmed Central) -  Apr 19, 2022   
    Although nanomedicines have been in the oncology field for almost three decades with the introduction of doxil, only a few nanomedicine products have reached approval...In this review, we summarized the current status of immunotherapy using PD-1/PD-L1-targeting nanocarriers. The knowledge on material science, therapeutic agents and formulation designs could pave the way for high-efficacy treatment outcomes.